INBX Inhibrx Biosciences, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2007919 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY550.0%
TTM net income YoY-108.3%
TTM EPS YoY-108.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-10,386.5%
Net margin-10,773.5%
FCF margin-9,986.5%
EBITDA margin-10,195.5%
Returns
ROE-197.8%
ROA-85.6%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets94.5%
Debt / equity12.58x
Current ratio3.93x
Interest coverage-11.07x
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.30M | $200,000 |
| R&D expense | $113.03M | $203.74M |
| SG&A expense | $23.30M | $127.91M |
| Operating income | -$135.03M | -$331.45M |
| Interest expense | $12.20M | $13.49M |
| Pretax income | -$140.05M | $1.69B |
| Income tax | $2,000 | $2,000 |
| Net income | -$140.06M | $1.69B |
| EBITDA | -$132.54M | -$329.16M |
| EPS (basic) | -9.04 | 114.01 |
| EPS (diluted) | -9.04 | 112.62 |
| Weighted avg. shares (diluted) | 15.49M | 14.98M |
| Balance sheet | ||
| Cash & equivalents | $124.22M | $152.60M |
| Current assets | $132.83M | $160.40M |
| PP&E, net | $3.73M | $6.20M |
| Total assets | $146.48M | $180.77M |
| Current liabilities | $33.80M | $40.73M |
| Long-term debt | $100.56M | $0 |
| Total debt | $100.56M | $0 |
| Total liabilities | $138.49M | $47.18M |
| Shareholders' equity | $7.99M | $133.58M |
| Net debt | -$23.66M | -$152.60M |
| Shares outstanding | 14.58M | 14.48M |
| Cash flow statement | ||
| Operating cash flow | -$129.79M | -$194.41M |
| Capital expenditure | $31,000 | $2.60M |
| Free cash flow | -$129.82M | -$197.01M |
| Investing cash flow | -$28,000 | -$2.60M |
| Financing cash flow | $101.45M | $71.68M |
| Depreciation & amortization | $2.48M | $2.29M |
| Stock-based compensation | $11.14M | $58.52M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.